Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 21;22(47):10275-10286.
doi: 10.3748/wjg.v22.i47.10275.

Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases

Affiliations
Review

Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases

Hannah Ceuleers et al. World J Gastroenterol. .

Abstract

Proteases, enzymes catalyzing the hydrolysis of peptide bonds, are present at high concentrations in the gastrointestinal tract. Besides their well-known role in the digestive process, they also function as signaling molecules through the activation of protease-activated receptors (PARs). Based on their chemical mechanism for catalysis, proteases can be classified into several classes: serine, cysteine, aspartic, metallo- and threonine proteases represent the mammalian protease families. In particular, the class of serine proteases will play a significant role in this review. In the last decades, proteases have been suggested to play a key role in the pathogenesis of visceral hypersensitivity, which is a major factor contributing to abdominal pain in patients with inflammatory bowel diseases and/or irritable bowel syndrome. So far, only a few preclinical animal studies have investigated the effect of protease inhibitors specifically on visceral sensitivity while their effect on inflammation is described in more detail. In our accompanying review we describe their effect on gastrointestinal permeability. On account of their promising results in the field of visceral hypersensitivity, further research is warranted. The aim of this review is to give an overview on the concept of visceral hypersensitivity as well as on the physiological and pathophysiological functions of proteases herein.

Keywords: Inflammatory bowel diseases; Irritable bowel syndrome; Protease inhibitors; Proteases; Proteinase-activated receptors; Visceral hypersensitivity; Visceral pain.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: No potential conflicts of interest.

Figures

Figure 1
Figure 1
Simplified representation of the concept of endo- and exopeptidases. Endopeptidases cleave internal peptide bonds. Exopeptidases cleave terminal peptide bonds; they can be subdivided into amino- and carboxypeptidases according to the position of the cleavage of the peptide bond. Aminopeptidases cleave at amino (NH2) terminal bonds, while carboxypeptidases cleave at carboxy (COOH) terminal bonds. Image constructed using the Servier Image Bank.
Figure 2
Figure 2
Classification of proteases based on the chemical structure of their active site. For each class, the chemical structure of the core residue in their active site is shown on top and a few examples with medical relevance of proteases belonging to that family are displayed below. MMP: Matrix metalloprotease.
Figure 3
Figure 3
Schematic representation of the activation of a protease-activated receptor. A protease cleaves the N-terminal domain (1), releasing a new N-terminus (2). The new N-terminus binds to the receptor as a tethered ligand, providing an intracellular signal (3). Image constructed using the Servier Image Bank. N-terminus: Amino-terminus; PAR: Protease-activated receptor.

Similar articles

Cited by

References

    1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–429. - PubMed
    1. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313:949–958. - PubMed
    1. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016 Epub ahead of print. - PubMed
    1. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205–217. - PubMed
    1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–721.e4. - PubMed

MeSH terms

Substances